Apellis Pharmaceuticals, Inc.
APLSDelisted May 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding Apellis Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 247 | 5 | 273 | +31 |
| Shares | 131.5M | 3.25M | 122.3M | −5.96M (−4.6%) |
| Value | $2.28B | $56.3M | $2.77B | +$549.5M (+24.7%) |
5 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (61)
Institutions that held Apellis Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (30)
Institutions that held Apellis Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (5)
Institutions that held Apellis Pharmaceuticals, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 2,367,224 | $41.0M |
| Camber Capital Management LP | 850,000 | $14.7M |
| HAP Trading, LLC | 17,937 | $310.5K |
| E Fund Management Co., Ltd. | 16,057 | $277.9K |
| Financial Gravity Companies, Inc. | 100 | $1.73K |